Pancreatic Cancer's Long Shot Pays Off: What This Breakthrough Means for Oncology's Future The approval of Rasonque, a once daily pill developed by Revolution Medicines to target pancreatic cancer's notorious RAS mutation, has sent shockwaves through the oncology community.
While investors are hailing this as a major win for Wall Street, the real significance lies in what it says about our understanding of cancer biology and the potential for future treatments.
Rasonque's approval marks a significant milestone in the quest to tame the RAS protein, which drives tumor growth in most pancreatic cancers and roughly a quarter of all human cancers.